ClinConnect ClinConnect Logo
Search / Trial NCT00000569

Lung Health Study II

Launched by UNIVERSITY OF MINNESOTA · Oct 27, 1999

Trial Information

Current as of May 11, 2025

Completed

Keywords

ClinConnect Summary

BACKGROUND:

Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States and a major cause of morbidity, is a spectrum of chronic lung diseases including clinical diagnoses of chronic bronchitis, emphysema, and combinations of both. Varying degrees of bronchoreactivity occur over the entire spectrum. Asthma and COPD have many features in common. Distinction is usually dependent on clinical features and clinical course. The diagnosis of asthma will not exclude a patient from the designation of COPD for this study, although criteria for exclusion inclu...

Gender

ALL

Eligibility criteria

  • Inclusion:
  • 1. Previously participated in or screened for the Lung Health Study I
  • 2. Ages 40 to 69
  • 3. Forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) \< 70 percent
  • 4. Forced expiratory volume at one second (FEV1) 30 to 90 percent predicted.
  • Exclusions:
  • 1. Cancer
  • 2. Recent myocardial infarction
  • 3. Alcoholism
  • 4. Heart Failure
  • 5. Insulin-dependent diabetes mellitus
  • 6. Neuropsychiatric disorders
  • 7. Used bronchodilators or oral or inhaled corticosteroids in previous year

About University Of Minnesota

The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.

Locations

Patients applied

0 patients applied

Trial Officials

John Connett

Principal Investigator

University of Minnesota

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials